Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
1.690
0.00 (0.00%)
Feb 18, 2026, 12:43 PM EST - Market open
Innate Pharma Employees
Innate Pharma had 174 employees as of June 30, 2025. The number of employees decreased by 7 or -3.87% since the number was reported on December 31, 2024.
Employees
174
Change
-7
Growth
-3.87%
Revenue / Employee
$85,286
Profits / Employee
-$310,817
Market Cap
159.81M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 174 | -7 | -3.87% |
| Dec 31, 2024 | 181 | 2 | 1.12% |
| Dec 31, 2023 | 179 | -32 | -15.17% |
| Dec 31, 2022 | 211 | -4 | -1.86% |
| Dec 31, 2021 | 215 | -29 | -11.89% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Editas Medicine | 246 |
| Fate Therapeutics | 181 |
| ProQR Therapeutics | 166 |
| Zentalis Pharmaceuticals | 166 |
| Adagene | 138 |
| Rani Therapeutics Holdings | 106 |
| Compugen | 74 |
| Connect Biopharma Holdings | 62 |
IPHA News
- 6 weeks ago - Number of Shares and Voting Rights of Innate Pharma as of December 31, 2025 - Business Wire
- 2 months ago - Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025 - Business Wire
- 2 months ago - Innate Pharma Releases Its 2026 Financial Calendar - Business Wire
- 2 months ago - Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025 - Business Wire
- 3 months ago - Innate Pharma to Present at Jefferies Global Healthcare Conference - Business Wire
- 3 months ago - Innate Pharma S.A. (IPHA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results - Business Wire
- 3 months ago - Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL - Business Wire